---
title: "ResMed Insiders Sold US$12m Of Shares Suggesting Hesitancy"
description: "ResMed Inc. insiders sold US$12 million worth of shares over the past year, raising concerns among shareholders. The largest sale was by Chief Product Officer Justin Leong, who sold US$10 million at U"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/231282808.md"
published_at: "2025-03-10T23:36:10.000Z"
---

# ResMed Insiders Sold US$12m Of Shares Suggesting Hesitancy

> ResMed Inc. insiders sold US$12 million worth of shares over the past year, raising concerns among shareholders. The largest sale was by Chief Product Officer Justin Leong, who sold US$10 million at US$217 per share, below the current price of US$232. No insiders bought shares during this period, and insider ownership stands at 0.5%. While insider selling is not a definitive negative signal, it suggests caution for potential investors. Analysts recommend monitoring insider transactions for better insights into company performance.

Many **ResMed Inc.** (NYSE:RMD) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for ResMed

## The Last 12 Months Of Insider Transactions At ResMed

Over the last year, we can see that the biggest insider sale was by the Chief Product Officer, Justin Leong, for US$10m worth of shares, at about US$217 per share. So it's clear an insider wanted to take some cash off the table, even below the current price of US$232. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. This single sale was 72% of Justin Leong's stake.

ResMed insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

I will like ResMed better if I see some big insider buys. While we wait, check out this **free** list of undervalued and small cap stocks with considerable, recent, insider buying.

## Does ResMed Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. ResMed insiders own 0.5% of the company, currently worth about US$180m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

## What Might The Insider Transactions At ResMed Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the ResMed insiders selling. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this **free** report showing analyst forecasts for its future.

But note: **ResMed may not be the best stock to buy**. So take a peek at this **free** list of interesting companies with high ROE and low debt.

*For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.*

If you're looking to trade ResMed, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

### Related Stocks

- [RMD.US - Resmed](https://longbridge.com/en/quote/RMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 在瑞思邁發佈財報之前你需要了解的內容 | 在瑞思邁財報發佈前你需要知道的事項 | [Link](https://longbridge.com/en/news/271486711.md) |
| 瑞思邁｜8-K：2026 財年 Q2 營收 14.23 億美元超過預期 |  | [Link](https://longbridge.com/en/news/274202441.md) |
| 瑞思邁的一位董事出售了 2000 股股票 | 瑞思邁董事出售 2,000 股股票 | [Link](https://longbridge.com/en/news/275076223.md) |
| 瑞思邁的首席法務官出售了公司 50 股普通股 | 瑞思邁首席法律官出售 50 股公司普通股 | [Link](https://longbridge.com/en/news/275076273.md) |
| 瑞思邁公司股票在週五下跌，表現遜於大盤 | 瑞思邁（ResMed Inc.，股票代碼：RMD）週五股價下跌 1.20%，收於 257.58 美元，表現不及大盤，標準普爾 500 指數下跌 0.06%，道瓊斯工業平均指數下跌 0.17%。此次下跌結束了該股連續兩天的上漲趨勢，目前股價比 | [Link](https://longbridge.com/en/news/272881717.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.